Advertisement
Mr. Jindong Zhou joined Simcere in 1994 and has over twenty years ofexperience in the pharmaceutical industry. Prior to his promotion, he servedas Vice President of Manufacturing overseeing several GMP manufacturing plants.As Executive Vice President, he broadens his responsibilities beyondmanufacturing to include sales and marketing and other executive officesupport.
Advertisement
Mr. Xiaojin Yin joined Simcere in 2000, and as Vice President of R&D heintroduced both Bicun and Endu to the Company together with many otherpipeline products. In his new role as Senior Vice President of R&D, he willcontinue to oversee the Company's R&D activities with a focus on bringing morepipeline products and senior R&D professionals to the Company.
Mr. Qingsen Li joins Simcere from Taikang Insurance Co. Ltd. where he wasGeneral Manager of Training and Human Resources. Prior to Taikang, Mr. Liheld the position of Vice President and Director of Human Resources atNovartis China.
Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere,commented: "We are delighted to promote Jindong Zhou and Xiaojin Yin to newpositions with increased management responsibilities. These executives havemade many valuable contributions to Simcere and we know their strongleadership and execution capabilities will continue to help Simcere achievefurther growth."
Mr. Ren added: "We are also pleased to welcome Qingsen Li to ourmanagement team. His vast experience with both local Chinese andmultinational companies will bring human resources at Simcere to a new leveland reinforces our commitment in bringing onboard the best quality talent intothe Company."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR; Simcere) is a leadingmanufacturer and supplier of branded generic pharmaceuticals and manufacturerof the patented anti-cancer biotech product Endu in the rapidly growing Chinamarket. In recent years, Simcere has been focusing its strategy on thedevelopment of first-to-market generic and innovative pharmaceuticals, and hasintroduced a first-to-market generic stroke management medication under thebrand name Bicun and an innovative anti-cancer medication under the brand nameEndu. Simcere currently manufactures and sells more than 50 pharmaceuticalproducts including antibiotics, anti-cancer medication and stroke managementmedication and is the exclusive distributor of three additionalpharmaceuticals that are marketed under its brand names. Simcere concentratesits research and development efforts on the treatment of diseases with highincidence and/or mortality rates and for which there is a clear demand formore effective pharmacotherapy such as cancer, strokes, osteoporosis andinfectious diseases and currently has more than 12 pipeline products. Formore information about Simcere Pharmaceutical Group, please visithttp://www.simcere.com .
SOURCE Simcere Pharmaceutical Group
